Aurinia Pharmaceuticals Inc (AUPH) Upgraded by Zacks Investment Research to Hold
- Author: Zachary Reyes Apr 11, 2017,
Apr 11, 2017, 21:54
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was upgraded by Zacks Investment Research from a "sell" rating to a "hold" rating in a note issued to investors on Monday.
Several other brokerages have also recently commented on AUPH.
Stock is now moving with a positive distance from the 200 day simple moving average of approximately 96.58%, and has a solid year to date (YTD) performance of 233.33% which means the stock is constantly adding to its value from the previous fiscal year end price.
11/02/2016 - Mackie began new coverage on Aurinia Pharmaceuticals Inc giving the company a "speculative buy" rating. Finally, Leerink Swann lifted their price target on shares of Aurinia Pharmaceuticals from $7.00 to $11.00 and gave the stock an "outperform" rating in a research report on Thursday, March 2nd. They now have a Dollars 12 price target on the stock. The stock has a current PEG of 8.59.
Aurinia Pharmaceuticals (NASDAQ:AUPH) last issued its quarterly earnings results on Thursday, March 9th.
Return on assets, on the other hand, measures a company's ability to turn assets such as cash, buildings, equipment, or inventory into more assets. In comparing the current price level of the equity to their moving averages, the shares are trading $4.17 off of the 50-day average of $231.82 and $12.64 away from the 200-day moving average of $223.35. The company's market capitalization is $385.75 million.
AUPH has a 1-year high price of $ 10.54 and 1-year low price of $1.74.
WARNING: This story was published by BBNS and is owned by of BBNS. If you are viewing this report on another domain, it was illegally copied and reposted in violation of USA & global trademark & copyright legislation.
A number of hedge funds have recently bought and sold shares of the stock. Redmile Group LLC raised its stake in Aurinia Pharmaceuticals by 560.4% in the third quarter. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.10. SG Americas Securities LLC acquired a new position in Aurinia Pharmaceuticals during the third quarter worth about $1,123,000.
Best time to invest in stock market is when things are on odd side, and it's not easy how to pick stocks.
Valeant Pharmaceuticals International, Inc.'s (NYSE:VRX) wholly owned subsidiary, Bausch + Lomb, reported that it has received 510 (k) clearance from the U.S. Food and Drug Administration (FDA) for the Stellaris Elite Vision Enhancement System, the company's next generation phacoemulsification cataract platform.
The event will feature presentations by key opinion leaders (KOLs) Samir Parikh, MD, Assistant Professor of Medicine, Nephrology at the Ohio State University Wexner Medical Center and Michael R. Bubb, MD, Associate Professor of Medicine, Rheumatology and Clinical Immunology at the University of Florida, who will present Aurinia's 48-week data from the AURA-LV (AURA) study of voclosporin for the treatment of active lupus nephritis (LN) and discuss the clinical implications of this data, respectively.